Diabetes Care in The Netherlands: - Novo Nordisk

More documents

Recommendations

Info

ContentsSummarized findings and recommendationsThe opportunity• Diabetes is a major and underestimated source of medical costs and lost productivity• Diabetes care in The Netherlands has reached a high level of quality, but there is still opportunity for further improvement• Further improving health of patients may lead to EUR 1.5-2 B of economic benefits in 2020The road• Refine economic incentives to encourage integrated care and quality improvement• Engage employers, UWV and participative care in diabetes care• Engage the patient’s social network to support self management• Introduce conditional market access models for new therapies and medication to assess behavioural impactAppendix: list of sources18
Already more than 1M diabetes patients in the Netherlands -Already more than 1M diabetes patients in the Netherlands -~100.000 more diagnosed than usually reportedNumber of Diabetes PatientsNumber of Diabetes Patients2010, ‘0002010, ‘00095-190~1.0-1.1M850920-975710Type 2557752795-875Total number of diabetes patientsthat use medication plus estimated10% to 15% patients that use nomedicationType 115398100-125CBS : based onpatient surveyRIVM based on sample ofGP registrations (2007figure extrapolated to 2010)Booz estimate(based on SFK dataon diabetesmedication users)Undiagnosed (basedon ’02-’04 study insouthwest NL) 1Total number of diabetespatients (estimated)(1) Based on study of 50-70 years old patients. Undiagnosed rate of 10-20% has been extrapolated. SFK reports 830.000 patients on diabetes medication. SFK data covers 92% of the market. We have notscaled up SFK numbers because there is also a fraction of over-registration SFK data (~5-10%) as some people taking medications from multiple pharmacies are counted twiceBooz & Company 14 November 2011Prepared for Novo NordiskSource: CBS, RIVM, SFK, Janssen et al. Screening study, Booz & Company Analysis1219
Page 6 and 7: SummaryDiabetes is a serious and de
Page 8: diabetes care. Extra compensation w
Page 11 and 12: ContentsSummarized findings and rec
Page 13 and 14: 11Diabetes is a major and underesti
Page 15 and 16: 33Further improving health of of di
Page 17 and 18: 22Recommendation 2: Engage employer
Page 19: 44Recommendation 4: Introduce condi
Page 23 and 24: Costs of of complications and treat
Page 25 and 26: Number of patients reaches ~1.4M in
Page 27 and 28: Increase in lost productivity is dr
Page 29 and 30: Diabetes care clearly improved in t
Page 31 and 32: Better compliance can be stimulated
Page 37 and 38: Delaying complications saves medica
Page 39 and 40: LimitedLimitedcollaborationcollabor
Page 41 and 42: Individual quality incentives are l
Page 43 and 44: Recommendation 1: Insurer should in
Page 47 and 48: Labour shortage from late nineties
Page 49 and 50: However, curative and participative
Page 53 and 54: Non-compliance leads to severe comp
Page 55: Facilitated patient networks are su
Page 58 and 59: Recommendation 3:Facilitate network
Page 62 and 63: But new medication could add a lot
Page 66: Booz & Company is a global manageme

Diabetes Care in The Netherlands: - Novo Nordisk

Create successful ePaper yourself

Delete template?

Save as template?